OM1, a Boston, MA-based real-world outcomes and technology company, closed a $50m Series C financing round.
The round was led by Scale Venture Partners, with participation from existing investors General Catalyst (GC), Polaris Partners, and 7wire Ventures. In conjunction with the funding, Rory O’Driscoll, Partner at Scale Venture Partner, has joined OM1’s Board of Directors.
The company intends to use the funds to expand its real-world data cloud and clinical registries for real-world evidence and personalized medicine.
Led by Dr. Richard Gliklich, CEO and founder, OM1 organizes health information and applies artificial intelligence (AI) technology to allow customers including healthcare stakeholders, including regulators, payers and providers to generate and use real-world evidence more rapidly and effectively to gain regulatory approval, to understand the effectiveness, safety and value of treatments, and to personalize care.
The company focuses on specific therapeutic areas, including chronic conditions like immunology, rheumatology, cardiometabolic disorders, musculoskeletal conditions and central nervous system (CNS)/behavioral health. Among the products developed are therapeutic-focused registries for advancing medical research, such as in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), and AI solutions for measuring and predicting outcomes for patients and populations.